Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
11.49
-0.03 (-0.26%)
At close: Oct 29, 2024, 4:00 PM
11.52
+0.03 (0.26%)
After-hours: Oct 29, 2024, 6:28 PM EDT
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $126.67M in the quarter ending June 30, 2024, with 34.04% growth. This brings the company's revenue in the last twelve months to $455.66M, up 29.98% year-over-year. In the year 2023, Amicus Therapeutics had annual revenue of $399.36M with 21.30% growth.
Revenue (ttm)
$455.66M
Revenue Growth
+29.98%
P/S Ratio
7.59
Revenue / Employee
$881,344
Employees
517
Market Cap
3.41B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | 182.24M | 90.99M | 99.72% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Perrigo Company | 4.43B |
Envista Holdings | 2.53B |
Prestige Consumer Healthcare | 1.11B |
Apellis Pharmaceuticals | 628.79M |
HUTCHMED (China) | 610.81M |
Axonics | 408.81M |
TG Therapeutics | 346.72M |
PROCEPT BioRobotics | 176.58M |
FOLD News
- 1 day ago - Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewsWire
- 8 days ago - American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas - GlobeNewsWire
- 8 days ago - 3 Attractive Biotechs With Recent Positives - Seeking Alpha
- 11 days ago - Amicus: Teva Settlement Clears Revenue Path Forward For Galafold - Seeking Alpha
- 12 days ago - Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Benzinga
- 12 days ago - Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva - GlobeNewsWire
- 25 days ago - Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024 - GlobeNewsWire
- 4 weeks ago - 'Boring' Amicus Therapeutics Is Making Progress - Seeking Alpha